Identification of the core motif of the BRCA2 C-terminal RAD51-binding domain by comparing canine and human BRCA2

• Published in: Journal of Veterinary Medical Science Vol. 83; no. 5; pp. 759 - 766
• Main Authors: YOSHIKAWA, Yasunaga, MORIMATSU, Masami, OCHIAI, Kazuhiko, ISHIGURO-OONUMA, Toshina, MORIOKA, Ryo, OKUDA, Kento, ORINO, Koichi
• Format: Journal Article
• Language: English
• Published: Japan JAPANESE SOCIETY OF VETERINARY SCIENCE 2021; Japan Science and Technology Agency; The Japanese Society of Veterinary Science
• Subjects: Amino Acid Sequence; Amino acids; Animals; Biochemistry; BRCA2; BRCA2 protein; BRCA2 Protein - genetics; C-terminal RAD51-binding domain; DNA Repair; Dog Diseases - genetics; Dogs; Female; Homologous recombination; Homologous recombination repair; Humans; interaction activity; Mammary Neoplasms, Animal - genetics; Mutation; Protein Binding; RAD51; Rad51 Recombinase - genetics; Rad51 Recombinase - metabolism; Recombinase; Tumor suppressor genes; Tumors; RAD51; BRCA2; C-terminal RAD51-binding domain; interaction activity
• ISSN: 0916-7250; 1347-7439
• DOI: 10.1292/jvms.21-0006

Mammary tumors are the most common tumors in women and non-spayed female dogs. One of the reasons for mammary tumors is mutations of the tumor suppressor gene, BRCA2. BRCA2 participates in homologous recombination repair by interacting with the RAD51 recombinase. BRCA2 has two RAD51-binding domains, consisting of BRC repeats and the C-terminal RAD51-binding domain, respectively. Although several studies have addressed the function of the C-terminal RAD51-binding domain of human BRCA2, the amino acid sequences required for the RAD51-interaction activity remain unclear. In this study, the C-terminal RAD51-binding domains of canine and human BRCA2 were compared; the canine domain displayed a weaker interaction with RAD51. This difference was attributed to the C-terminal portion of the domain via a comparison between canine and human domains. Furthermore, peptides shorter than those previously reported displayed RAD51-interacting activity, and a core motif of this domain consisting of 25 amino acids was identified. Since a mutation (S3323N) was reported in the core motif of this domain, the effect of this mutation was evaluated. The mutant exhibited similar RAD51-binding activity as that of the wild-type protein, suggesting that the mutation was functionally neutral. These data suggested that the C-terminal portion of the BRCA2 C-terminal RAD51-binding domain influenced its RAD51-interaction activity, and a minimum core motif of 25 amino acids was identified in this domain. These data may help clarify BRCA2 function, as well as the tumorigenic effects of BRCA2 mutation.